Astrocytic Ferroptosis: An Integrative Hub Linking Metabolic Dyshomeostasis, Glial Crosstalk, and Neurodegeneration in Alzheimer’s Disease
aging and disease · 2026
DOI: 10.14336/ad.2026.0328 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift aging and disease, 2026. Verfasst von Zhimin Lu und 7 weiteren Autor:innen. Beteiligte Einrichtung: College of Management, Qilu Medical University, Zibo, Shandong, 250300, China.
Themen: Demenz
Abstract (Originalsprache)
Alzheimer’s disease (AD) is a widespread age‑related neurodegenerative disorder. Current therapies targeting Aβ plaques and hyperphosphorylated Tau show limited efficacy. The core pathology of AD involves neuroglial metabolic network collapse, which is tightly associated with brain iron dyshomeostasis and abnormal ferroptosis. As the main iron storage and antioxidant cells in the CNS, astrocytes transform into disease‑associated astrocytes under AD conditions. Metabolic reprogramming switches them from a neuroprotective to a pro-ferroptotic phenotype, contributing to thereby exacerbating systemic metabolic dyshomeostasis. This review systematically elaborates the regulatory mechanisms of astrocytic ferroptosis in AD: disordered iron metabolism (e.g., aberrant DMT1/FPN1 expression) induces iron accumulation as the initiation prerequisite; excessive oxidative stress (Ang II/HIF-1α-NOX4 axis-mediated ROS generation) and impaired antioxidant defense (Nrf2-SLC7A11/GPX4 inactivation, ApoE4 dysfunction) serve as core regulatory modules; FTH1 and SAT1 dysregulation elevates the labile iron pool, while AQP4 dysfunction impairs metabolite clearance, amplifying ferroptosis. Moreover, aberrant crosstalk among astrocytes, microglia and oligodendrocytes exacerbates AD-related neurodegeneration. Collectively, astrocytic ferroptosis acts as a key integrative mechanism linking iron dysmetabolism, oxidative stress, neuroinflammation and Aβ/Tau pathology, offering a potential new avenue for decoding AD pathogenesis. Targeting astrocytic ferroptosis is expected to overcome the long-standing therapeutic limitations of conventional AD treatments, providing theoretical support and new directions for developing disease-modifying AD therapies. While individual components including disease-associated astrocytes, brain iron dyshomeostasis, NOX4- and NRF2-related ferroptosis have been documented separately, this review represents the first comprehensive synthesis that identifies astrocytic ferroptosis as a central hub that unifies these fragmented mechanisms into a cohesive pathogenic cascade driving AD.
Autor:innen und Institutionen
- College of Management, Qilu Medical University, Zibo, Shandong, 250300, China.
- College of Sport and Health, Shandong Sport University, Jinan, Shandong, 250102, China.
Zitieren
APA
Lu, Z., Meng, C., Ren, X., Zhang, S., Xu, X., Hao, S., Wang, Q., & Zhou, D. (2026). Astrocytic Ferroptosis: An Integrative Hub Linking Metabolic Dyshomeostasis, Glial Crosstalk, and Neurodegeneration in Alzheimer’s Disease. aging and disease. https://doi.org/10.14336/ad.2026.0328
Vancouver
Lu Z, Meng C, Ren X, Zhang S, Xu X, Hao S, et al. Astrocytic Ferroptosis: An Integrative Hub Linking Metabolic Dyshomeostasis, Glial Crosstalk, and Neurodegeneration in Alzheimer’s Disease. aging and disease. 2026. doi:10.14336/ad.2026.0328
BibTeX
@article{Lu2026,
author = {Lu, Zhimin and Meng, Chang and Ren, Xiaoyan and Zhang, Shuo and Xu, Xinqing and Hao, Shaofei and Wang, Qinglu and Zhou, Daoqing},
title = {Astrocytic Ferroptosis: An Integrative Hub Linking Metabolic Dyshomeostasis, Glial Crosstalk, and Neurodegeneration in Alzheimer’s Disease},
journal = {aging and disease},
year = {2026},
doi = {10.14336/ad.2026.0328}
}
EUVIMED